Sinopharm Group
China’s centrally administered pharmaceutical and healthcare group spanning drug research, biopharmaceuticals, vaccines, medical devices, distribution, retail, healthcare services and international trade.
Last updated October 9, 2026
AI crawler reads
77requests
5AI- OpenAI53
- Perplexity9
- Anthropic6
- Amazon5
- Meta4
- Profile
- 58
- Controversies
- 10
- JSON · MD
- 0
- First read
- Nov 5, 2026
- Latest read
- Nov 17, 2026
From this site's server log
Overview
Sinopharm Group, formally China National Pharmaceutical Group Corporation, is one of China's largest state-owned healthcare enterprises. Its activities cover pharmaceutical research and manufacturing, vaccines and biological products, active pharmaceutical ingredients, traditional Chinese medicine, medical devices, pharmaceutical distribution, retail pharmacy, logistics, engineering, and healthcare-related services. The group is commonly known internationally as Sinopharm and should be distinguished from Sinopharm Group Co., Ltd., a publicly traded distribution and healthcare subsidiary of the wider China National Pharmaceutical Group system. The organization developed from China's state pharmaceutical administration and industrial infrastructure. Its position combines commercial operations with a strategic public-health role: the group supplies medicines and medical products to hospitals, pharmacies, public-health institutions, and other customers, while its research and manufacturing units participate in national vaccine and biologics programs. The central government, through the State-owned Assets Supervision and Administration Commission of the State Council, exercises ownership oversight over the parent group. Sinopharm's business is organized through a broad network of manufacturing and distribution companies. Major activities include prescription medicines, over-the-counter products, vaccines, blood products, diagnostic products, chemical ingredients, biological medicines, medical equipment, and healthcare supply-chain services. Its distribution businesses connect domestic and multinational pharmaceutical manufacturers with hospitals and other healthcare providers across China. This gives the group a role not only as a producer but also as a national-scale intermediary in the country's medicine-supply system. The group became especially visible during the COVID-19 pandemic through China National Biotec Group, or CNBG, and its Beijing and Wuhan biological-product institutes. These units developed and manufactured inactivated COVID-19 vaccines that were supplied in China and exported or donated to other countries. The World Health Organization listed the Sinopharm COVID-19 vaccine for emergency use in 2021, supporting its deployment through international procurement and vaccine-sharing programs. The pandemic strengthened Sinopharm's international profile but also led to scrutiny of vaccine efficacy data, transparency, and the broader governance of Chinese vaccine development. Sinopharm's public identity therefore combines industrial scale, state ownership, healthcare infrastructure, and pharmaceutical branding. It is not a single consumer product label: it is a diversified corporate group whose products and services are delivered through numerous subsidiaries and institutional brands. Its current strategic importance lies in securing medicine supplies, expanding innovative and biological medicines, developing vaccines and diagnostics, improving distribution efficiency, and supporting China's broader healthcare and life-sciences objectives. Sinopharm is the common English name of China National Pharmaceutical Group Co., Ltd., one of China’s largest state-owned pharmaceutical and healthcare conglomerates. The company operates as a broad industry platform rather than as a single-product consumer brand. Its activities extend across pharmaceutical research and manufacturing, vaccines and blood products, chemical medicines, traditional Chinese medicine, medical devices, pharmaceutical distribution, retail pharmacies, healthcare services, engineering, exhibitions, investment and international trade. The group was established on November 26, 1998, as a holding company bringing together several national pharmaceutical and medical-supply enterprises, including China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation, China National Pharmaceutical Foreign Trade Corporation and China National Medical Device Corporation. In 2009, it was merged with China National Biotec Group, substantially strengthening its biotechnology, vaccine and blood-product capabilities. The resulting organization became a centrally administered state-owned enterprise supervised by China’s State-owned Assets Supervision and Administration Commission. Sinopharm’s business model combines industrial manufacturing with commercial circulation. Through subsidiaries such as China National Biotec Group and major pharmaceutical manufacturers, the group produces vaccines, plasma-derived and other biological products, chemical medicines and traditional Chinese medicines. Through Sinopharm Group Co., Ltd., its principal commercial subsidiary, it distributes medicines, medical equipment, consumables and healthcare products to hospitals, community health institutions, pharmacies and other distributors. Sinopharm Holding also operates retail pharmacy networks and supply-chain services. This vertical structure gives the group a role in several stages of the healthcare value chain, from research and production to warehousing, delivery, retail and clinical support. The group’s most internationally recognizable product achievement was the Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV. Developed by the Beijing Institute of Biological Products under China National Biotec Group, the vaccine used an inactivated-virus platform and was designed for storage and distribution at ordinary refrigerated temperatures. Following clinical studies in several countries, the World Health Organization listed the vaccine for emergency use on May 7, 2021, enabling its use through international procurement and COVAX-related channels. Sinopharm also developed a second inactivated COVID-19 vaccine through the Wuhan Institute of Biological Products. Although the COVID-19 vaccines brought the Sinopharm name to global public attention, the group’s underlying business is much broader. Its portfolio includes biological medicines, vaccines for infectious diseases, blood products, modern Chinese medicines, generic and specialty chemical drugs, medical imaging and treatment equipment, laboratory products, hospital supplies and pharmaceutical logistics. The company also works with foreign pharmaceutical, medical-device and healthcare companies to import products into China, localize manufacturing, develop distribution networks and pursue regulatory approvals. Sinopharm has expanded its international role through exports, overseas production collaborations, medical-aid projects, hospital construction and participation in global healthcare programs. In 2026, the group described its international operations as reaching more than 70 countries and regions, with Belt and Road markets serving as an important area for expansion. Its international strategy includes vaccine technology cooperation, local production arrangements, medical-equipment supply and overseas healthcare infrastructure. The group’s ownership structure is complex because many operating businesses are separately incorporated and publicl…
History
China National Pharmaceutical Group Corporation emerged from China's state pharmaceutical administration and industrial system and was established in 1987. It was created to coordinate pharmaceutical manufacturing, research, distribution, and related healthcare activities at a national level. Over time, the organization consolidated a wide range of enterprises involved in chemical medicines, biological products, vaccines, traditional Chinese medicine, medical equipment, pharmaceutical commerce, and logistics. The group operates under the oversight of China's central state-asset administration system. Unlike a focused pharmaceutical company, it functions as a diversified healthcare conglomerate. Its manufacturing companies develop and produce medicines and biological products, while its commercial subsidiaries distribute products to hospitals, pharmacies, public-health agencies, and other healthcare institutions. The group also has engineering, research, import and export, retail, and supply-chain capabilities. This structure has made it an important part of China's national medicine-distribution infrastructure. A major component of the group is China National Biotec Group, generally known as CNBG. CNBG brings together vaccine and biological-product institutes, including major Beijing and Wuhan facilities. These organizations have long worked on human vaccines, blood products, diagnostic reagents, and other biological medicines. Their work includes products for infectious diseases and public-health programs as well as commercial healthcare markets. Sinopharm also developed an important listed-company platform. Sinopharm Group Co., Ltd. was established as a pharmaceutical distribution and healthcare company and later listed in Hong Kong. It is associated with the broader Sinopharm group but is not identical to the parent corporation. Other group companies operate in manufacturing, medical devices, retail pharmacy, and specialized biological-product businesses. The group's corporate architecture consequently includes both wholly controlled state-owned entities and publicly traded subsidiaries. The COVID-19 pandemic brought Sinopharm's vaccine operations to global attention. CNBG units developed inactivated SARS-CoV-2 vaccines, and Chinese regulators authorized their use in late 2020. The vaccines were then supplied domestically and internationally. In May 2021, the World Health Organization granted emergency-use listing to the Sinopharm vaccine, making it eligible for international procurement mechanisms and contributing to vaccination programs in countries across Asia, Africa, Latin America, and the Middle East. Sinopharm's pandemic role included manufacturing, export, donations, and participation in broader diplomatic and public-health efforts. The pandemic period also generated criticism and debate. International observers and researchers sought more detailed clinical-trial information and real-world effectiveness data than was initially available publicly. Questions about evidence transparency and the performance of inactivated vaccines were discussed alongside broader debates about vaccine access, regulatory review, and the role of state-owned pharmaceutical companies. These issues did not end Sinopharm's international deployment, but they shaped the scrutiny attached to its vaccines. In its present form, Sinopharm remains a broad healthcare platform rather than a single-product brand. Its strategic priorities include maintaining medicine and vaccine supply, upgrading manufacturing, expanding biological and innovative medicines, developing diagnostics and medical devices, and improving national distribution networks. The group continues to serve domestic institutional healthcare demand while pursuing selected international sales, partnerships, and public-health projects. Sinopharm’s institutional history reflects the consolidation of China’s national pharmaceutical, medical-device and healthcare-supply assets into a centrally coordinated corporate group. The organization was formally created on November 26, 1998, under the name China National Pharmaceutical Group Corporation. Rather than being founded by a single entrepreneur, it was assembled as a holding company for several existing state-owned entities: China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation, China National Pharmaceutical Foreign Trade Corporation and China National Medical Device Corporation. The creation of the group gave the Chinese government a national platform for coordinating pharmaceutical manufacturing, foreign trade, medical-device production and the distribution of essential healthcare products. During its early development, Sinopharm combined industrial assets with commercial and trading operations. Its companies manufactured medicines and medical products while also importing, exporting and distributing products for domestic and overseas suppliers. This structure allowed the group to participate in both production and circulation, an important capability in China’s large and geographically dispersed healthcare system. Over time, the group expanded its activities into chemical pharmaceuticals, traditional Chinese medicine, medical devices, healthcare services, pharmaceutical logistics and retail pharmacy. A decisive turning point came in 2009, when Sinopharm was merged with China National Biotec Group. CNBG brought together important biological-product capabilities, including vaccine and blood-product research and production. The merger increased Sinopharm’s role in public-health manufacturing and created the institutional base for later vaccine development. It also linked the group more closely to China’s national immunization and biological-products infrastructure. Another major phase involved the development of Sinopharm’s commercial platform. Sinopharm Group Co., Ltd., established in Shanghai in January 2003, became the group’s principal pharmaceutical and medical-device distribution arm. Its shares were listed on the Hong Kong Stock Exchange in September 2009 under stock code 01099. Sinopharm Group developed a nationwide network serving hospitals, primary-care institutions, pharmacies, distributors and other healthcare customers. Its subsidiaries included China National Medicines Corporation and China National Accord Medicines, both of which became separately listed companies. The parent Sinopharm group retained indirect influence through holding companies and investment structures, while the listed subsidiaries operated as distinct legal entities. The group’s industrial portfolio also broadened through the integration of major manufacturers and research organizations. Shanghai Shyndec Pharmaceutical, for example, became part of Sinopharm in 2010 and later participated in restructuring and integration of the chemical-pharmaceutical sector. Other significant businesses included China National Biotec Group, the Beijing and Wuhan institutes of biological products, Taiji Group and various pharmaceutical, medical-device and healthcare-service subsidiaries. Through these entities, Sinopharm developed a portfolio covering vaccines, blood products, chemical medicines, traditional Chinese medicines and medical equipment. Sinopharm’s public profile changed dramatically during the COVID-19 pandemic. Its Beijing Institute of Biological Products and Wuhan Institute of Biological Products developed inactivated-virus vaccine candidates in 2020. The Beijing product, generally known as BBIBP-CorV or the Sinopharm BIBP vaccine, entered international clinical studies and was used in vaccination programs in multiple regions. The product’s conventional refrigerated storage requirements made it operationally attractive for countries without extensive ultra-cold-chain infrastructure. On May 7, 2021, the World Health Organization listed the BIBP vaccine for emergency use. This made it eligible for international procurement through COVAX-related channels and helped establish Sinopharm as one of the most visible Chinese healthcare brands worldwide. The pandemic also accelerated the group’s investment in vaccine capacity, international partnerships and technology cooperation. Sinopharm worked with governments, manufacturers and healthcare companies in countries including the United Arab Emirates, Egypt, Morocco, Serbia, Bangladesh and others on clinical research, manufacturing, filling, distribution and regulatory access. The group later emphasized broader internationalization beyond COVID-19 vaccines, including overseas production arrangements for vaccines, exports of medicines and traditional Chinese medicines, medical-equipment projects and hospital construction. Sinopharm’s history also includes a significant quality-control controversy. In 2017, Chinese regulatory sampling identified a DPT vaccine batch made by the Wuhan Institute of Biological Products that failed potency requirements. Regulators stated that 400,520 doses were affected and attributed the problem primarily to a temporary filling-equipment malfunction that caused uneven distribution of the vaccine suspension. Unused doses were recalled and destroyed, the subsidiary was fined and the company was required to improve equipment maintenance, filling procedures, staff training and quality controls. The episode became part of the wider 2018 Chinese vaccine-safety crisis and placed renewed attention on manufacturing oversight and public confidence. In the 2020s, Sinopharm pursued a dual strategy: reinforce its core role in pharmaceutical manufacturing and distribution while moving toward digital, international and service-oriented healthcare operations. It expanded collaboration with global companies such as Pfizer, Elekta, Medtronic, Abbott, Siemens Healthineers and other international suppliers. It also increased participation in the China International Import Expo, used procurement partnerships to bring foreign medical technologies into China and promoted traditional Chinese medicine products in overseas markets. By 2026, Sinopharm presented itself as a comprehensive healthcare group with one of China’s broadest pharmaceutical industry chains. Its activities included biopharmaceuticals, vaccines, blood products, chemical medicines, traditional Chinese medicine, medical equipment, pharmaceutical distribution, retail pharmacies, healthcare services, engineering, investment and international business. Its continuing significance derives from the combination of state ownership, industrial scale, distribution reach, public-health responsibilities and the ability to connect domestic healthcare demand with international suppliers and markets.
- 2026
International business described as reaching more than 70 countries and regions
[13]Sinopharm reported expanding exports, vaccine localization, overseas healthcare projects and Belt and Road cooperation across more than 70 countries and regions.
- 2025
Tongtian Oral Liquid authorized in Canada
[14]A traditional Chinese medicine product from Sinopharm’s Taiji Group received Canadian authorization as a Natural Health Product.
- 2024
University of Macau strategic cooperation
[18]Sinopharm signed a strategic cooperation framework with the University of Macau covering life-health research and related cooperation.
- 2023
Pfizer cooperation agreement
[15]Pfizer and Sinopharm Group agreed to cooperate on regulatory approval and market access for innovative Pfizer medicines in China.
- 2021
WHO emergency-use listing for Sinopharm BIBP vaccine
[3]The WHO lists the Sinopharm COVID-19 vaccine for emergency use, enabling its inclusion in international procurement and vaccine-sharing programs.
- 2020
Chinese authorization of Sinopharm COVID-19 vaccines
[3]Inactivated COVID-19 vaccines developed by CNBG units receive Chinese authorization and begin wider domestic deployment.
- 2020
Sinopharm COVID-19 vaccine candidates enter clinical development
[17]Sinopharm’s Beijing and Wuhan biological-product institutes advanced inactivated COVID-19 vaccine candidates into clinical trials and international cooperation.
- 2018
Recall, destruction and regulatory rectification of DPT vaccine
[12]Unused doses were recalled and destroyed; the Wuhan subsidiary was fined and required to improve manufacturing controls and equipment maintenance.
- 2017
Substandard DPT vaccine identified at Wuhan subsidiary
[12]Regulatory sampling identified an ineffective-potency DPT vaccine batch made by Wuhan Institute of Biological Products.
- 2010
Shanghai Shyndec becomes part of Sinopharm
[16]Shanghai Shyndec Pharmaceutical was incorporated into Sinopharm in April 2010 and later participated in chemical-pharmaceutical restructuring.
Products and positioning
A state-owned, nationally scaled Chinese healthcare and pharmaceutical platform combining manufacturing, vaccines and biologics, medical products, pharmaceutical distribution, and healthcare services. A state-backed, vertically integrated pharmaceutical and healthcare group positioned as a national healthcare-supply platform, major Chinese medicine and medical-device distributor, vaccine producer and international healthcare partner.
Inactivated vaccine · 2020
Sinopharm BIBP COVID-19 vaccine
An inactivated SARS-CoV-2 vaccine developed and manufactured by units of China National Biotec Group. It was used in China's domestic vaccination program and supplied internationally. WHO emergency-use listing in 2021 enabled its consideration for international procurement and deployment. An inactivated-virus COVID-19 vaccine developed by Sinopharm’s Beijing Institute of Biological Products under China National Biotec Group. Known as BBIBP-CorV or the BIBP vaccine, it was tested in international Phase III studies and received WHO emergency-use listing on May 7, 2021. Its conventional refrigerated storage requirements supported distribution in countries without extensive ultra-cold-chain infrastructure. A second inactivated-virus COVID-19 vaccine developed by Sinopharm’s Wuhan Institute of Biological Products. The product was developed separately from the Beijing BIBP vaccine and formed part of Sinopharm’s pandemic vaccine portfolio.
Vaccines
Human vaccines
Sinopharm's biological-product businesses develop and manufacture vaccines for infectious diseases and public-health programs. The portfolio is produced through specialized institutes and manufacturing companies rather than through one uniform consumer-facing product line.
Healthcare distribution · 2003
Pharmaceutical distribution services
The group's distribution operations supply prescription medicines, biological products, medical devices, and other healthcare goods to hospitals, pharmacies, clinics, and public-health institutions. This is one of Sinopharm's defining capabilities and is particularly significant in China's institutional healthcare market. Through Sinopharm Group, the company distributes medicines, medical devices, consumables and healthcare products to hospitals, community health institutions, pharmacies and other distributors. The business includes warehousing, delivery, supply-chain management and value-added services.
Biologics
Biological products and blood products
Sinopharm companies manufacture and distribute biological medicines, blood-derived products, diagnostic materials, and related products. These activities are concentrated in specialized biological-product subsidiaries and research institutes.
Medical technology
Medical devices and diagnostics
The group participates in medical-device, diagnostic, laboratory, and healthcare-equipment businesses, complementing its pharmaceutical manufacturing and distribution activities.
Biopharmaceuticals
Vaccines and biological products
Sinopharm’s biological-products portfolio includes preventive vaccines, blood products, immunological products and other biotechnology-based medicines produced through China National Biotec Group and affiliated institutes. These products support national immunization, infectious-disease prevention and broader clinical use.
Pharmaceutical medicines
Chemical pharmaceuticals
The group manufactures and distributes a wide range of chemical medicines, including generic and specialty products. Its chemical-pharmaceutical operations have been supported by industrial restructuring, research institutes, manufacturing subsidiaries and Sinopharm’s large distribution network.
Traditional Chinese medicine
Traditional Chinese medicine portfolio
Sinopharm’s TCM activities include proprietary medicines, oral liquids and herbal preparations produced by subsidiaries such as Taiji Group. Products are marketed in China and, for selected formulations, in international markets including Singapore, Malaysia and Canada.
Medical devices
Medical-device distribution and supply-chain services
Sinopharm distributes diagnostic, surgical, imaging, laboratory, treatment and hospital-support equipment. It also works with international manufacturers to introduce advanced devices and healthcare technologies into the Chinese market.
Retail healthcare
Retail pharmacy and healthcare services
The group’s commercial subsidiaries operate retail pharmacies, professional pharmacy formats, direct-to-patient services, retail clinics and related healthcare platforms. These businesses connect Sinopharm’s wholesale network with consumers and community-based healthcare delivery.
Controversies
2021
Medical specialists warn against Sinopharm vaccine use in Sri Lanka
The Association of Medical Specialists warned against using the Sinopharm vaccine in Sri Lanka, citing an expert panel's conclusion that the available data were insufficient to determine its safety, efficacy and immunogenicity.
2017
Substandard DPT vaccine batch produced by Wuhan Institute of Biological Products
Chinese regulatory sampling found that a DPT vaccine batch produced by Sinopharm’s Wuhan Institute of Biological Products failed potency requirements. Regulators reported that 400,520 doses were affected. The stated cause was a temporary filling-equipment malfunction that made the vaccine suspension uneven. Unused doses were recalled and destroyed, and the subsidiary was fined and required to strengthen equipment maintenance, filling procedures, training and quality controls.
Ineffective DPT vaccine incident (2017)
Brand decisions
2019
Guoyao Technology subsidiary agrees to acquire 40% of Wing Yin HoldingsM&ABackground
Guoyao Technology announced that its wholly owned subsidiary, Zhongcai Enterprise Management, entered into an agreement on December 12 to acquire a 40% stake in Wing Yin Holdings for HK$41.6 million, paid through consideration shares.
Recent events
Roche Pharma China and Sinopharm sign a strategic cooperation framework agreement[21]
Reported
Roche Pharma China and Sinopharm Holding signed a strategic cooperation framework agreement at the China International Import Expo.
Merck and Sinopharm sign molnupiravir cooperation framework[22]
Reported
Merck and Sinopharm announced that they had signed a cooperation framework agreement. Under the agreement, Merck grants Sinopharm distribution and exclusive import rights in China for molnupiravir if the drug is approved there; the parties will also assess the feasibility of technology transfer.
Brii Biosciences and Sinopharm form strategic commercialization partnership[23]
Reported
Brii Biosciences announced that its controlled company, 腾盛华创, had entered a strategic partnership with Sinopharm to advance the China commercialization of the BRII-196/BRII-198 combination therapy, including drug reserves, distribution channels, and regional access.
Hua Medicine and Sinopharm establish supply-chain partnership[24]
Reported
Hua Medicine and Sinopharm signed a supply-chain strategic cooperation agreement covering logistics and warehousing, supply-chain management, and channel digitalization, to support commercialization of dorzagliatin in China after approval.
Sinopharm entities and Bangladesh sign vaccine cooperation memo[25]
China National Pharmaceutical Group subsidiaries China National Medicines Corporation and China National Biotec Group, together with Bangladesh's Ministry of Health and Family Welfare, signed a memorandum of cooperation on filling and packaging inactivated COVID-19 vaccines.
Juyi Technology completes Series B financing[26]
Reported
Juyi Technology completed a Series B financing of more than RMB 100 million, jointly led by Legend Capital and YuanBio Venture Capital, with other investors participating.
- Unconfirmed
Medical specialists warn against Sinopharm vaccine use in Sri Lanka[20]
Reported
The Association of Medical Specialists warned against using the Sinopharm vaccine in Sri Lanka, citing an expert panel's conclusion that the available data were insufficient to determine its safety, efficacy and immunogenicity.
Mingji Biotech completes RMB 300 million Series B financing[27]
Reported
Mingji Biotech announced that it completed a Series B financing totaling RMB 300 million, led by CICC Qide Fund, with existing investor Lilly Asia Ventures and other institutions participating.
- Unconfirmed
Knightsbridge Circle offers a China-developed vaccine travel service[28]
Reported
The Knightsbridge Circle offered a travel service for members and prospective members to travel to the UAE and receive a COVID-19 vaccine developed by China National Pharmaceutical Group, subject to membership or a stated fee and travel and accommodation costs.
Sinopharm Holdings appoints Yu Qingming as board chairman[29]
Reported
On January 14, Sinopharm Holdings announced that its board had elected Yu Qingming as board chairman, as well as chairman of the board’s strategy and investment committee and nomination committee.
Sources34 sources
- 1Sinopharm official corporate websitesinopharm.com
- 2Sinopharm Group Co., Ltd. official websitesinopharmgroup.com
- 3WHO lists additional COVID-19 vaccine for emergency usewho.int
- 4China National Pharmaceutical Group Corporationen.wikipedia.org
- 5品牌文化sinopharm.com
- 6现代中药sinopharm.com
- 7国际经营sinopharm.com
- 8Sinopharm (company)en.wikipedia.org
- 9Sinopharm leadershipen.sinopharm.com
- 10Sinopharm Group Co., Ltd. official profileen.sinopharm.com
- 11WHO background document on Sinopharm BIBP vaccinewho.int
- 12Chinese regulator information on Wuhan DPT vaccinexinhuanet.com
- 13Sinopharm international expansion reporten.sinopharm.com
- 14Sinopharm Tongtian Oral Liquid authorization in Canadaen.sinopharm.com
- 15Pfizer-Sinopharm strategic cooperation reportfinance.yahoo.com
- 16Shanghai Shyndec becomes part of Sinopharmen.sinopharm.com
- 17Sinopharm COVID-19 vaccine candidates enter clinical developmenten.wikipedia.org
- 18University of Macau strategic cooperationen.sinopharm.com
- 19Guoyao Technology subsidiary agrees to acquire 40% of Wing Yin Holdingsfinance.sina.com.cn
- 20Medical specialists warn against Sinopharm vaccine use in Sri Lankaisland.lk
- 21罗氏制药中国与国药控股签署战略合作框架协议prnasia.com
- 22默沙东与国药集团签署莫诺拉韦合作框架协议prnasia.com
- 23腾盛博药与国药控股达成战略合作prnasia.com
- 24华领医药与国药控股签署供应链战略合作协议prnasia.com
- 25国药集团与孟加拉国签署疫苗合作备忘录jl.chinanews.com.cn
- 26巨翊科技完成B轮融资finance.sina.com.cn
- 27明济生物完成3亿元B轮融资finance.sina.com.cn
- 28骑士桥联合会推出中国疫苗旅行服务finance.sina.com.cn
- 29国药控股选举于清明为董事长finance.sina.com.cn
- 30Summer Atlantic Capital 与国药集团签署战略合作协议prweb.com
- 31复星医药与国药控股签署疫苗物流合作协议finance.sina.com.cn
- 32劲方医药完成B轮融资tech.sina.com.cn
- 33国药控股荣获“最佳港股通公司”奖finance.sina.com.cn
- 34独家丨复星医药与国药控股签署关于BioNTech mRNA新冠疫苗物流合作协议finance.sina.com.cn
Cite this profile: Cite the canonical profile. /brandpedia/国药集团 · Editorial policy · How profiles are compiled